PLSCR1参与白血病细胞分化的过程，是目前分化诱导疗法治疗AML的研究热点。传统化疗药物应用于AML治疗，副作用大，缓解率低，而分化诱导疗法药物副作用明显减少，因此新的治疗AML的分化诱导剂亟待开发。文献报道汉黄芩素具有较强的体外抗白血病作用，汉黄芩苷是汉黄芩素的体内主要活性代谢产物，有关汉黄芩苷诱导人AML细胞分化的作用国内外文献未见报道。本课题组初步研究表明，在AML细胞系中，汉黄芩苷能诱导细胞发生周期阻滞和分化及上调PLSCR1的表达，并能抑制裸鼠移植瘤的生长；在人AML原代细胞中，汉黄芩苷能诱导细胞分化并延长原代细胞接种NOD/SCID小鼠的生存期。本项目旨在深入探讨汉黄芩苷抗AML作用机制，并研究它对AML细胞系及人原代细胞中PLSCR1去棕榈酰化后入核激活IP3R1启动子，从而影响钙离子功能的调控过程，为阐明其抗AML的确切机制提供新依据，同时为天然产物治疗白血病提供新思路。

PLSCR1 is a lipid-binding protein that has been proposed to accelerate redistribution of plasma membrane phospholipids between the inner and outer leaflets. It also plays potential roles in hematopoiesis and leukemogenesis. Traditional chemical therapy shows toxic side effects and low remission rate in acute myeloid leukemia. Differentiation therapy has been reported to show less toxicology and side effects, therefore, new differentiation inductors are required to be discovered. It is reported that wogonin has strong effects of anti-leukemia in vitro, wogonoside is the main metabolites that play activity in vivo, our study shows that wogonoside not only induced the cycle arrest and differentiation of AML cell lines (HL-60,U937 cell) but also up-regulated expression of PLSCR1, at the same time, preliminary study showed that wogonoside had strong activity to AML primary cells both in vivo and in vitro. The differentiation induction effects of wogonoside in AML cell and regulation of PLSCR1 function have not been reported. This project aims to study the regulation process that under the action of wogonoside, PLSCR1 activates IP3R1 promoter in nucleus after depalmitoylation, thus affecting the function of calcium ion as well as the mechanism of action to AML primary cells in vivo and in vitro, at the same time, to provide new evidence for clarify the mechanism of wogonin in anti-leukemia and new approach to the study of treatment for leukemia with natural products.